Tag Archives: Andrew Witty

Arise Sir Andrew (Witty)

By Guest Blogger | Published: January 4, 2012
Big Pharma received a nod in the UK’s New Year’s Honours List this week when a knighthood was duly bestowed upon GSK’s Andrew Witty — making him ‘Sir Andrew’ to you and me. For once, though, receiving such an honor did not exactly place him in totally exalted company.
Posted in Global, Op-Ed, leadership | Also tagged , , | Leave a comment

It's Industry's Problem: A Fresh Take on R&D Costs

By William Looney | Published: October 19, 2011
High in-house failure rates are slowing progress on pricing affordability, says GSK CEO Andrew Witty. If there is one message that big pharma has applied consistently over the years, it is that drug development is very expensive. Big bucks and long-term investment in the institutional know-how and capacity built exclusively through private enterprise are what count [...]
Posted in Global, IP, R&D, leadership | Also tagged , , , | 2 Comments

Europe: New Vision, Old Ideas

By Guest Blogger | Published: June 27, 2011
Europe: New Vision, Old Ideas The European industry is making saintly noises about collaboration, but vestiges of the old dogma remain, says Reflector. If you want to know what the Vatican is thinking, a pontifical high mass is a good place to start. If you want to know what the European pharmaceutical industry is thinking, you can [...]
Posted in Europe, Guest Blog, Regulatory | Also tagged , , , | Leave a comment

Europe’s Fiscal Crisis: Can Big Pharma Emerge Unscathed?

By William Looney | Published: June 2, 2010
Europe’s current fiscal crisis, symbolized by the meltdown in Greece, is seen by big pharma as a temporary situation to be taken in stride—after all, the EU southern and eastern tier, with its chronically shaky finances and per capita incomes as low as a third of the EU norm, has historically been a marginal player [...]
Posted in Europe | Also tagged , , , , , | 2 Comments

Merck, Lilly, Pfizer: One for All and All for One

By Oriana Schwindt | Published: February 24, 2010
Just a month after Andrew Witty’s announcement that GSK will make more than 13,500 of its malaria compounds available to all, Pfizer, Merck, and Eli Lilly have thrown their do-gooder hats into the ring as well. Together, the three drug giants will pull together an undisclosed dollar amount in seed funding and create the independent, non-profit [...]
Posted in Strategy | Also tagged , , , , , , | 1 Comment